Haematological Cancer Survivors

The population living with and beyond haematological cancer is increasing because incidence and survival have risen. Haematological cancers and their treatments make infection risk biologically plausible because cancers can impair immunity and treatments are often immunosuppressive. Grouping haematological cancers together can hide subtype-specific infection risks. Haematological malignancies include leukaemia, lymphoma, multiple myeloma, and other blood cancers. The review focuses on long-term infection incidence and mortality among haematological cancer survivors compared with people without cancer history or the general population.